RESULTS
The cliniical diagnoses of the fifteen patients investigated together with their plasma calcium concentrations during prolothan G therapy are given in Table I . Of the fifteen patients, only one (case 14), who had an initial plasma calcium concentration of 1458 mg./100 ml., failed to show a lowering of plasma calcium concentration which was maintained.
Three of the patients (cases 2, 3 and 11) also received intravenous infusions of prolothan A which was without effect on the plasma calcium concentration (Fig. 1 The uriniary calcium excretion in two patients who were made hypocalcaemic with prolothan-Gr did not fall pari passu with the plasma calcium concentration. The lowest urinary calcium values were found three or four days after the lowest plasma calcium concentration and in fact the urinary calcium excretion was at its lowest after the therapy when the plasma calcium concentration was returning to normal. The 47Ca blood-bone dynamics of the same two patients did not differ from normal (Anderson, Osborn, Tomlinson and Wall, 1964) .
Prolothan A even in large doses did not exhibit the hypocalcaemic effect of prolothani G. Both prolothan A and prolothan G are aqueous solutions of protaniine standardised to contain nitrogen 2 50% w/v., the former as a complex with sodium-formaldehyde-bisulphite, the latter with the addition of 40%w/v dextrose. It would seem therefore that the complexing with sodium-formaldehyde-bisulphite destroys the hypocalcaemic properties of the protamine. Prolothan G possesses heparin neutralisation properties, whereas prolothan A has no measurable neutralising effect on heparin.
Protamiine is used clinically as an antidote for excessive heparinisation. Heparin is also known to be a potent bone resorption factor. Goldhaber (1965) has reported that heparin markedly enhanced the parathormone, vitamin A, and vitamin D induced resorption in a tissue culture preparation without having any appreciable activity alone. It is possible therefore that protamine acts by blocking the bone resorption enhancement property of heparin, or some other acid mucopolysaccharide, resulting in hypocalcaemia.
Hypercalcaemia is a frequent complication in patients with malignant tumours (Woodard, 1953; Swyer, Berger, Gordon and Laszlo, 1950 15 ) responded to prolothan G therapy while the hypercalcaemia of case 14 wA,as unresponsive to the therapy. It would appear from the normal 47Ca blood-boIne dynamics of the patients studied (cases 6 and 15) that the prolothan G lhad Ino direct effect on the normal exchange and accretion processes in bone precluding any acute parathormone blocking action.
Thyrocalcitonin lowers the plasma calcium concentration in patienlts (Foster, Joplin, Maclntyre, Melvin and Slack, 1966) and it lowers the serum calcium and serum phosphorus concentrations in the intact animal (Milhaud, Perault and Moukhtar, 1965) . The plasma inorganic phosphorus concentrations in our patients during prolothan therapy was variable and it is unlikely that the hypocalcaemia could be attributed to a thyrocalcitonin effect.
The plasma sodium and potassium concentrations remained within normal limits during prolothan infusion and this excludes a general effect oIn the adrenal gland. The changes in plasma calcium were not due to changes in plasma proteins as the total protein concentration was also unaffected during the infusionl. There was no change in the serum alkaline phosphatase.
The only consistent finding was the hypocalcaemia and its aetiology is uncertain but it is suggested that it could be due to the inhibition of the bonle resorption enhancing effect of heparin.
SUMMARY
The effect of prolothan G and prolothan A on calcium metabolism in patienits with malignancy is described. Therapeutic doses of prolothan G produced hypocalcaemia in fourteen of the fifteen patients studied. Its possible mode of action in calcium homeostasis is discussed.
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